| MeSH term | MeSH ID | Detail |
|---|---|---|
| Vestibulocochlear Nerve Diseases | D000160 | 1 associated lipids |
| Acromegaly | D000172 | 6 associated lipids |
| Actinobacillus Infections | D000189 | 4 associated lipids |
| Actinomycosis | D000196 | 2 associated lipids |
| Addison Disease | D000224 | 3 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Adrenal Hyperplasia, Congenital | D000312 | 2 associated lipids |
| Albuminuria | D000419 | 18 associated lipids |
| Alzheimer Disease | D000544 | 76 associated lipids |
| Angina, Unstable | D000789 | 14 associated lipids |
7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Qiang YW et al. | Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. | 2008 | Blood | pmid:18305214 |
| Sauer AV et al. | ADA-deficient SCID is associated with a specific microenvironment and bone phenotype characterized by RANKL/OPG imbalance and osteoblast insufficiency. | 2009 | Blood | pmid:19633200 |
| Chagraoui H et al. | Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO. | 2003 | Blood | pmid:12506018 |
| Kastritis E et al. | Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging. | 2015 | Blood Cancer J | pmid:26047389 |
| Nihrane A et al. | Depletion of the Shwachman-Diamond syndrome gene product, SBDS, leads to growth inhibition and increased expression of OPG and VEGF-A. | 2009 Jan-Feb | Blood Cells Mol. Dis. | pmid:19014892 |
| Brändström H et al. | A single nucleotide polymorphism in the promoter region of the osteoprotegerin gene is related to intima-media thickness of the carotid artery in hypertensive patients. The Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA). | 2004 | Blood Press. | pmid:15223723 |
| Tsirpanlis G | Is inflammation the link between atherosclerosis and vascular calcification in chronic kidney disease? | 2007 | Blood Purif. | pmid:17261926 |
| Cianciolo G et al. | Coronary calcifications in end-stage renal disease patients: a new link between osteoprotegerin, diabetes and body mass index? | 2010 | Blood Purif. | pmid:19816015 |
| Cozzolino M | Emerging roles for osteoprotegerin and receptor activator of nuclear factor-kappaB in the vascular system. | 2009 | Blood Purif. | pmid:19729903 |
| Lee JH et al. | Tumor necrosis factor-α converting enzyme (TACE) increases RANKL expression in osteoblasts and serves as a potential biomarker of periodontitis. | 2011 | BMB Rep | pmid:21777519 |
| Narita N et al. | A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer. | 2008 | BMC Cancer | pmid:18684318 |
| Goswami S and Sharma-Walia N | Osteoprotegerin secreted by inflammatory and invasive breast cancer cells induces aneuploidy, cell proliferation and angiogenesis. | 2015 | BMC Cancer | pmid:26608463 |
| Ney JT et al. | Genetic polymorphism of the OPG gene associated with breast cancer. | 2013 | BMC Cancer | pmid:23369128 |
| Niu Y et al. | Association of plasma osteoprotegerin levels with the severity of lower extremity arterial disease in patients with type 2 diabetes. | 2015 | BMC Cardiovasc Disord | pmid:26260869 |
| Sponder M et al. | Endurance training significantly increases serum endocan but not osteoprotegerin levels: a prospective observational study. | 2017 | BMC Cardiovasc Disord | pmid:28056805 |
| Nagy EE et al. | High circulating osteoprotegerin levels are associated with non-zero blood groups. | 2016 | BMC Cardiovasc Disord | pmid:27387019 |
| Liu M et al. | Semen Astragali Complanati- and Rhizoma Cibotii-enhanced bone formation in osteoporosis rats. | 2013 | BMC Complement Altern Med | pmid:23782721 |
| Fathilah SN et al. | Labisia pumila regulates bone-related genes expressions in postmenopausal osteoporosis model. | 2013 | BMC Complement Altern Med | pmid:24007208 |
| Wei CC et al. | Total glucosides of paeony prevents juxta-articular bone loss in experimental arthritis. | 2013 | BMC Complement Altern Med | pmid:23870279 |
| Shen Y et al. | (5R)-5-Hydroxytriptolide (LLDT-8) inhibits osteoclastogenesis via RANKL/RANK/OPG signaling pathway. | 2015 | BMC Complement Altern Med | pmid:25887296 |
| Shuid AN et al. | Eurycoma longifolia upregulates osteoprotegerin gene expression in androgen- deficient osteoporosis rat model. | 2012 | BMC Complement Altern Med | pmid:22967165 |
| Niu Y et al. | Association of osteoprotegerin with impaired glucose regulation and microalbuminuria: the REACTION study. | 2015 | BMC Endocr Disord | pmid:26626139 |
| Fortner RT et al. | Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort. | 2017 | BMC Med | pmid:28173834 |
| Piedra M et al. | "Single nucleotide polymorphisms of the OPG/RANKL system genes in primary hyperparathyroidism and their relationship with bone mineral density". | 2011 | BMC Med. Genet. | pmid:22185226 |
| Kulcsar-Jakab E et al. | Cystatin C as a potential predictor of osteoprotegerin levels in healthy men, a cross-sectional, observational study. | 2015 | BMC Musculoskelet Disord | pmid:26311162 |
| Kauther MD et al. | Calcitonin substitution in calcitonin deficiency reduces particle-induced osteolysis. | 2011 | BMC Musculoskelet Disord | pmid:21843355 |
| Kim CH et al. | Effects of high frequency loading on RANKL and OPG mRNA expression in ST-2 murine stromal cells. | 2009 | BMC Musculoskelet Disord | pmid:19728893 |
| Evans CE et al. | Age of donor alters the effect of cyclic hydrostatic pressure on production by human macrophages and osteoblasts of sRANKL, OPG and RANK. | 2006 | BMC Musculoskelet Disord | pmid:16519799 |
| Lv Y et al. | Effects of pamidronate disodium on the loss of osteoarthritic subchondral bone and the expression of cartilaginous and subchondral osteoprotegerin and RANKL in rabbits. | 2014 | BMC Musculoskelet Disord | pmid:25377946 |
| Ma J et al. | Up-regulation of multiple proteins and biological processes during maxillary expansion in rats. | 2008 | BMC Musculoskelet Disord | pmid:18366685 |
| Zhou DA et al. | Influence of glucocorticoids on the osteogenic differentiation of rat bone marrow-derived mesenchymal stem cells. | 2014 | BMC Musculoskelet Disord | pmid:25027542 |
| Taylan A et al. | Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis. | 2012 | BMC Musculoskelet Disord | pmid:23025387 |
| Pateinakis P et al. | Associations of fetuin-A and osteoprotegerin with arterial stiffness and early atherosclerosis in chronic hemodialysis patients. | 2013 | BMC Nephrol | pmid:23758931 |
| Janda K et al. | Cardiovascular risk in chronic kidney disease patients: intima-media thickness predicts the incidence and severity of histologically assessed medial calcification in radial arteries. | 2015 | BMC Nephrol | pmid:26037625 |
| Rzepka R et al. | Soluble receptors for advanced glycation end products and receptor activator of NF-κB ligand serum levels as markers of premature labor. | 2015 | BMC Pregnancy Childbirth | pmid:26059227 |
| Jiang H et al. | A randomized controlled trial of pre-conception treatment for periodontal disease to improve periodontal status during pregnancy and birth outcomes. | 2013 | BMC Pregnancy Childbirth | pmid:24321402 |
| Duan P et al. | Gene polymorphisms in RANKL/RANK/OPG pathway are associated with ages at menarche and natural menopause in Chinese women. | 2015 | BMC Womens Health | pmid:25884698 |
| Pivonka P et al. | Model structure and control of bone remodeling: a theoretical study. | 2008 | Bone | pmid:18514606 |
| Asaba Y et al. | Urinary gamma-glutamyltransferase (GGT) as a potential marker of bone resorption. | 2006 | Bone | pmid:16942925 |
| O'Connor RD et al. | Mecp2 deficiency decreases bone formation and reduces bone volume in a rodent model of Rett syndrome. | 2009 | Bone | pmid:19414073 |
| O'Brien EA et al. | Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane. | 2001 | Bone | pmid:11182380 |
| Bendre MS et al. | Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. | 2003 | Bone | pmid:12919697 |
| Bi Y et al. | Biglycan deficiency increases osteoclast differentiation and activity due to defective osteoblasts. | 2006 | Bone | pmid:16364709 |
| Ralston SH | Pathogenesis of Paget's disease of bone. | 2008 | Bone | pmid:18672105 |
| Bateman TA et al. | Osteoprotegerin mitigates tail suspension-induced osteopenia. | 2000 | Bone | pmid:10773583 |
| Canon J et al. | Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis. | 2010 | Bone | pmid:20215062 |
| Verdrengh M et al. | RANKL-targeted therapy inhibits bone resorption in experimental Staphylococcus aureus-induced arthritis. | 2010 | Bone | pmid:19879986 |
| Zhang Y et al. | Differential mRNA expression profiles in proximal tibia of aged rats in response to ovariectomy and low-Ca diet. | 2009 | Bone | pmid:18848653 |
| Gruber R et al. | Platelet-released supernatants stimulate formation of osteoclast-like cells through a prostaglandin/RANKL-dependent mechanism. | 2002 | Bone | pmid:11996911 |
| Proposed standard nomenclature for new tumor necrosis factor members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature. | 2000 | Bone | pmid:11113385 | |
| Silva HC et al. | Higher prevalence of morphometric vertebral fractures in patients with recent coronary events independently of BMD measurements. | 2013 | Bone | pmid:23142805 |
| Kanematsu M et al. | Vector-averaged gravity regulates gene expression of receptor activator of NF-kappaB (RANK) ligand and osteoprotegerin in bone marrow stromal cells via cyclic AMP/protein kinase A pathway. | 2002 | Bone | pmid:11934645 |
| Li X et al. | Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice. | 2002 | Bone | pmid:11934647 |
| Seriwatanachai D et al. | Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio. | 2008 | Bone | pmid:18166509 |
| Vanella L et al. | HO-1 expression increases mesenchymal stem cell-derived osteoblasts but decreases adipocyte lineage. | 2010 | Bone | pmid:19853072 |
| Ueland T et al. | No associations between OPG gene polymorphisms or serum levels and measures of osteoporosis in elderly Australian women. | 2007 | Bone | pmid:16949901 |
| Walker CG et al. | Osteopontin is required for unloading-induced osteoclast recruitment and modulation of RANKL expression during tooth drift-associated bone remodeling, but not for super-eruption. | 2010 | Bone | pmid:20828639 |
| El-Hoss J et al. | Modulation of endochondral ossification by MEK inhibitors PD0325901 and AZD6244 (Selumetinib). | 2014 | Bone | pmid:24269278 |
| Zheng Y et al. | Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. | 2007 | Bone | pmid:17092788 |
| Sasaki N et al. | Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis. | 2002 | Bone | pmid:12052453 |
| Peng S et al. | The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin. | 2011 | Bone | pmid:21925296 |
| Xu M et al. | Basal bone phenotype and increased anabolic responses to intermittent parathyroid hormone in healthy male COX-2 knockout mice. | 2010 | Bone | pmid:20471507 |
| Zheng D et al. | The beneficial effect of Icariin on bone is diminished in osteoprotegerin-deficient mice. | 2012 | Bone | pmid:22551876 |
| Uemura H et al. | Circulating osteoprotegerin in women during GnRH-agonist treatment and their relationships with mineral components and biomarkers of bone turnover. | 2003 | Bone | pmid:14623063 |
| Liu J et al. | Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice. | 2008 | Bone | pmid:18337202 |
| Ostrowska Z et al. | RANKL/RANK/OPG system and bone status in females with anorexia nervosa. | 2012 | Bone | pmid:22001124 |
| Saidenberg-Kermanac'h N et al. | TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. | 2004 | Bone | pmid:15542046 |
| Ho TY et al. | Effects of relaxin and estrogens on bone remodeling markers, receptor activator of NF-kB ligand (RANKL) and osteoprotegerin (OPG), in rat adjuvant-induced arthritis. | 2011 | Bone | pmid:21419242 |
| Ueland T et al. | Growth hormone substitution increases gene expression of members of the IGF family in cortical bone from women with adult onset growth hormone deficiency--relationship with bone turn-over. | 2003 | Bone | pmid:14555269 |
| Nagata N et al. | Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population. | 2003 | Bone | pmid:14555278 |
| LaCroix AZ et al. | OPG and sRANKL serum levels and incident hip fracture in postmenopausal Caucasian women in the Women's Health Initiative Observational Study. | 2013 | Bone | pmid:23735608 |
| Bord S et al. | The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. | 2003 | Bone | pmid:12633785 |
| Reginster JY et al. | Strontium ranelate treatment increases osteoprotegerin serum levels in postmenopausal osteoporotic women. | 2012 | Bone | pmid:22270053 |
| Wada N et al. | Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha. | 2004 | Bone | pmid:15336598 |
| Kacena MA et al. | Megakaryocyte-mediated inhibition of osteoclast development. | 2006 | Bone | pmid:16782418 |
| Bataille C et al. | Different sympathetic pathways control the metabolism of distinct bone envelopes. | 2012 | Bone | pmid:22326888 |
| Wuyts W et al. | Evaluation of the role of RANK and OPG genes in Paget's disease of bone. | 2001 | Bone | pmid:11165949 |
| Ren W et al. | Effect of oral erythromycin therapy in patients with aseptic loosening of joint prostheses. | 2009 | Bone | pmid:19154802 |
| Liang QQ et al. | The expression of osteoprotegerin is required for maintaining the intervertebral disc endplate of aged mice. | 2011 | Bone | pmid:21466864 |
| Kiviranta R et al. | Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. | 2005 | Bone | pmid:15664014 |
| Mulcahy LE et al. | RANKL and OPG activity is regulated by injury size in networks of osteocyte-like cells. | 2011 | Bone | pmid:20854946 |
| Aspenberg P et al. | Targeting RANKL for reduction of bone loss around unstable implants: OPG-Fc compared to alendronate in a model for mechanically induced loosening. | 2011 | Bone | pmid:20858557 |
| Mossetti G et al. | Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment. | 2005 | Bone | pmid:15777635 |
| Janssens K et al. | An intermediate form of juvenile Paget's disease caused by a truncating TNFRSF11B mutation. | 2005 | Bone | pmid:15777670 |
| Valenta A et al. | Combined treatment with PTH (1-34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats. | 2005 | Bone | pmid:15869920 |
| Fukushima H et al. | IL-1-induced receptor activator of NF-kappa B ligand in human periodontal ligament cells involves ERK-dependent PGE2 production. | 2005 | Bone | pmid:15780952 |
| Regmi A et al. | Suramin interacts with RANK and inhibits RANKL-induced osteoclast differentiation. | 2005 | Bone | pmid:15780954 |
| Irie A et al. | Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. | 2007 | Bone | pmid:17560185 |
| Abrahamsen B et al. | Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins. | 2005 | Bone | pmid:15781001 |
| Dunn MD et al. | Local delivery of osteoprotegerin inhibits mechanically mediated bone modeling in orthodontic tooth movement. | 2007 | Bone | pmid:17588510 |
| Balga R et al. | Tumor necrosis factor-alpha: alternative role as an inhibitor of osteoclast formation in vitro. | 2006 | Bone | pmid:16580896 |
| Bord S et al. | Megakaryocytes modulate osteoblast synthesis of type-l collagen, osteoprotegerin, and RANKL. | 2005 | Bone | pmid:15794927 |
| Dimitri P et al. | Adipokines, bone-derived factors and bone turnover in obese children; evidence for altered fat-bone signalling resulting in reduced bone mass. | 2011 | Bone | pmid:20932948 |
| Ulrich-Vinther M et al. | Gene therapy with human osteoprotegerin decreases callus remodeling with limited effects on biomechanical properties. | 2005 | Bone | pmid:16169783 |
| Romas E et al. | Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. | 2002 | Bone | pmid:11856640 |
| Fahrleitner A et al. | Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation. | 2003 | Bone | pmid:12584041 |
| Buckley KA et al. | Adenosine triphosphate stimulates human osteoclast activity via upregulation of osteoblast-expressed receptor activator of nuclear factor-kappa B ligand. | 2002 | Bone | pmid:12477572 |
| Atkins GJ et al. | Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. | 2001 | Bone | pmid:11336917 |
| Komine M et al. | Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture. | 2001 | Bone | pmid:11344046 |
| Mori K et al. | DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process. | 2007 | Bone | pmid:17196895 |